Institute for Regenerative Medicine (IREM): Organization Update
After four years of service, Professors Roger Nitsch and Christoph Hock announced today that they will resign from the IREM Board of Directors of the Institute for Regenerative Medicine (IREM) by March 31, 2020.
Roger Nitsch and Christoph Hock will continue their tenure at IREM as part-time professors and lecturers in bio-entrepreneurship. They will continue to coach their respective IREM research groups. The reduction in workload at IREM will provide them with additional time for tending to their executive functions at Neurimmune, a UZH spin-off company, that they had co-founded in 2006.
As new Deputy Director Professor Reichenbach will be proposed for election by the Institute Assembly. The UZH has appointed Janine Reichenbach as Associate Professor for Somatic Gene Therapy at IREM as of February 1, 2020. She develops gene therapy for children with hereditary diseases in collaboration with the Children’s Hospital Zurich.
Together with the current Managing Director Professor Hoerstrup, Professor Reichenbach will oversee IREM's operations, and represent IREM's interests at the faculties as well as at the Executive Board of the University.
The Founding Directors Professors Nitsch, Hock and Hoerstrup established IREM in 2016 with the aim of building an integrated research and innovation unit by combining excellent science with advanced therapy development, and a training program in bio-entrepreneurship for young researchers. With the existing faculty, Professors Janine Reichenbach, Simon P. Hoerstrup, Roger M. Nitsch, Christoph Hock, Senior Professor Martin Schwab and the Assistant Professors and ERC Fellows Max Emmert and Ataman Sendoel, the IREM is well positioned for continuous academic excellence and success.